SofWave Medical Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Louis Scafuri

İcra Kurulu Başkanı

US$1.1m

Toplam tazminat

CEO maaş yüzdesi	47.6%
CEO görev süresi	5.3yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2yrs
Yönetim Kurulu ortalama görev süresi	5.2yrs

Son yönetim güncellemeleri

We Think Some Shareholders May Hesitate To Increase SofWave Medical Ltd.'s (TLV:SOFW) CEO Compensation

Sep 11

Recent updates

We Think Some Shareholders May Hesitate To Increase SofWave Medical Ltd.'s (TLV:SOFW) CEO Compensation

Sep 11

SofWave Medical Ltd. (TLV:SOFW) Screens Well But There Might Be A Catch

May 02

Even With A 27% Surge, Cautious Investors Are Not Rewarding SofWave Medical Ltd.'s (TLV:SOFW) Performance Completely

Jan 31

A Piece Of The Puzzle Missing From SofWave Medical Ltd.'s (TLV:SOFW) 31% Share Price Climb

Nov 17

We're Not Worried About SofWave Medical's (TLV:SOFW) Cash Burn

Nov 13

Here's Why We're Not Too Worried About SofWave Medical's (TLV:SOFW) Cash Burn Situation

May 05

Here's Why We're Not Too Worried About SofWave Medical's (TLV:SOFW) Cash Burn Situation

Dec 22

Is SofWave Medical (TLV:SOFW) In A Good Position To Invest In Growth?

Aug 25

CEO Tazminat Analizi

Louis Scafuri'un ücretlendirmesi SofWave Medical'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$4m
Mar 31 2024	n/a	n/a	-US$5m
Dec 31 2023	US$1m	US$547k	-US$8m
Sep 30 2023	n/a	n/a	-US$12m
Jun 30 2023	n/a	n/a	-US$15m
Mar 31 2023	n/a	n/a	-US$18m
Dec 31 2022	US$837k	US$508k	-US$20m

Tazminat ve Piyasa: Louis 'nin toplam tazminatı ($USD 1.15M ), IL pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 636.08K ).

Tazminat ve Kazançlar: Louis şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Louis Scafuri (72 yo)

5.3yrs

Görev süresi

US$1,148,000

Tazminat

Mr. Louis Scafuri serves as the Chief Executive Officer at SofWave Medical Ltd.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Louis Scafuri	Chief Executive Officer	5.3yrs	US$1.15m	Veri yok
Ariel Sverdlik	Co-Founder & CTO	9.8yrs	US$342.00k	9.68% ₪ 64.2m
Assaf Korner	Chief Financial Officer	3.2yrs	US$934.00k	0.74% ₪ 4.9m
Genady Nahshon	COO & Site Manager	no data	US$523.00k	Veri yok
Ruthie Amir	Vice President of Medicine	no data	US$310.00k	Veri yok
Shimon Eckhouse	Co-Founder & Chairman	9.8yrs	Veri yok	24.8% ₪ 164.5m
James Bartholomeusz	Chief Innovation Officer	less than a year	Veri yok	Veri yok
LIna Omari	Chief Digital Officer	less than a year	Veri yok	Veri yok
Larry Laber	Executive VP of North American Sales	less than a year	Veri yok	Veri yok
Tali Malach	Vice President of Quality	no data	Veri yok	Veri yok

2.0yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: SOFW 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Shimon Eckhouse	Co-Founder & Chairman	9.8yrs	Veri yok	24.8% ₪ 164.5m
Lisa Haimovitz	Independent Outside Director	3.5yrs	Veri yok	0.0069% ₪ 46.1k
Dominick Arena	Independent Director	5.8yrs	Veri yok	1.05% ₪ 7.0m
Orly Zilberman	External Director	3.3yrs	Veri yok	Veri yok
Sarit Soukari Ben Yohenan	External Director	3.3yrs	Veri yok	Veri yok
Yoav Moshe Sebba	Director	5.3yrs	Veri yok	Veri yok
Assaf Mansour	Director	5.2yrs	Veri yok	Veri yok

5.2yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SOFW 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.2 yıldır).

SofWave Medical Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

We Think Some Shareholders May Hesitate To Increase SofWave Medical Ltd.'s (TLV:SOFW) CEO Compensation

SofWave Medical Ltd. Appoints Larry Laber to the Role of Executive Vice President, North American Sales

SofWave Medical Ltd. Appoints James Bartholomeusz as Chief Innovation Officer

Less than half of directors are independent

SofWave Medical Ltd., Annual General Meeting, Jan 23, 2024

Less than half of directors are independent

Recent updates

SofWave Medical Ltd. to Report Q3, 2024 Results on Nov 13, 2024

SofWave Medical Ltd. Obtains U.S. Patent for Fat Tissue Reduction Technology

We Think Some Shareholders May Hesitate To Increase SofWave Medical Ltd.'s (TLV:SOFW) CEO Compensation

SofWave Medical Ltd. Appoints Larry Laber to the Role of Executive Vice President, North American Sales

Sofwave Receives FDA Clearance for Pure Impact™ in Strengthening and Firming of Arms in the U.S

Second quarter 2024 earnings released: US$0.045 loss per share (vs US$0.083 loss in 2Q 2023)

First quarter 2024 earnings released: US$0.029 loss per share (vs US$0.11 loss in 1Q 2023)

SofWave Medical Ltd. (TLV:SOFW) Screens Well But There Might Be A Catch

Full year 2023 earnings released: US$0.24 loss per share (vs US$0.57 loss in FY 2022)

SofWave Medical Ltd. Appoints James Bartholomeusz as Chief Innovation Officer

Even With A 27% Surge, Cautious Investors Are Not Rewarding SofWave Medical Ltd.'s (TLV:SOFW) Performance Completely

SofWave Medical Ltd. Receives FDA Clearance of Superb™? Technology for Improvement of the Appearance of Skin Laxity on the Upper Arm

Less than half of directors are independent

SofWave Medical Ltd., Annual General Meeting, Jan 23, 2024

A Piece Of The Puzzle Missing From SofWave Medical Ltd.'s (TLV:SOFW) 31% Share Price Climb

We're Not Worried About SofWave Medical's (TLV:SOFW) Cash Burn

Third quarter 2023 earnings released: US$0.036 loss per share (vs US$0.13 loss in 3Q 2022)

SofWave Medical Ltd. to Report Q3, 2023 Results on Nov 08, 2023

Sofwave Medical Announces FDA Clearance of SUPERB™ Technology For Treatment of Acne Scars

Second quarter 2023 earnings released: US$0.083 loss per share (vs US$0.16 loss in 2Q 2022)

New major risk - Share price stability

SofWave Medical Ltd. to Report Q2, 2023 Results on Aug 08, 2023

Sofwave Medical Ltd. Gains Additional U.S. Patent Protection for the Company's Proprietary SUPERB™ Technology

Less than half of directors are independent

First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.16 loss in 1Q 2022)

Here's Why We're Not Too Worried About SofWave Medical's (TLV:SOFW) Cash Burn Situation

Full year 2022 earnings released: US$0.57 loss per share (vs US$0.29 loss in FY 2021)

SofWave Medical Ltd. Gains Market Approval for SUPERB(TM) Non-Invasive Wrinkle Reduction and Lifting Technology in Mexico

Sofwave Medical Ltd Announces Market Approvals for SUPERB(TM) Non-Invasive Wrinkle Reduction Technology Now Extend to Taiwan

Here's Why We're Not Too Worried About SofWave Medical's (TLV:SOFW) Cash Burn Situation

SofWave Medical Ltd. Announces FDA Clearance of SUPERB™ Technology For Cellulite

SofWave Gains Approval to Market the Superb™ Non-Invasive Wrinkle Reduction Device in Brazil

Sofwave Medical Ltd. Receives Grants U.S. Patent Covering Key Elements of Proprietary Superb™ Non-Surgical Skin and Collagen Remodeling Technology

SofWave Medical Ltd. to Report Q2, 2022 Results on Aug 16, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

SofWave Medical Ltd. to Report Q4, 2022 Results on Mar 09, 2022

Chief Financial Officer Michael Eden has left the company

Is SofWave Medical (TLV:SOFW) In A Good Position To Invest In Growth?

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş